$30 Million

Argos Therapeutics Inc

At-the-market Offering

Argos Therapeutics Inc is a biopharmaceutical company. It is engaged in the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. Its product candidates include rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus.